Clinical Trials

With a key grant from Breakthrough T1D, MannKind aims its inhaled insulin at children. Is this a life-changing innovation or a high-stakes corporate revival?

A Canadian biotech is developing a novel cancer drug. We look beyond the paid promotions to analyze the science, the strategy, and the high-stakes reality.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

Right Brain Bio is leveraging Dassault Systèmes' powerful MEDIDATA platform to accelerate a radical new therapy that could reverse Parkinson's pathology.

Veristat isn't just hiring; it's assembling a brain trust to conquer biotech's toughest frontiers. Here's the story behind its strategic talent grab.

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

In a head-to-head battle, Takeda's zasocitinib showed superior skin clearance over a key competitor, signaling a potential new standard for oral therapy.

With millions suffering from chronic gout, Atom Therapeutics' new drug promises more than relief—it aims to reverse damage. Is this the breakthrough?

With a $43M funding boost, Irish innovator CroíValve is expanding trials for its unique 'Adaptive Coaptation' device, aiming to transform treatment for millions.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

With a sub-$10M market cap and blockbuster data, IMUNON's CEO faces a critical test: convince Wall Street its ovarian cancer drug is the real deal.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

For bladder cancer patients facing bladder removal, a novel therapy from Sweden offers new hope. A US trial expansion targets the most resistant cases.

A projected 12.4% CAGR signals a boom in hematopoietic stem cell transplantation, but the real story lies in the science poised to overcome timeless hurdles.

Parexel's new biotech incubator isn't just another funding vehicle. It's a strategic move to embed regulatory expertise at the seed stage, betting that early guidance is more valuable than capital alone.

SeaStar Medical prepares to present its life-saving organ failure technology to investors. We explore its newly approved product, pivotal adult trial, and vast market potential.

Australian radiopharma innovator AdvanCell is planting its flag in Greater Boston with a new HQ and factory, a strategic move to scale its potent Lead-212 therapy.